dc.contributor.author | Freeman, Fiona | |
dc.contributor.author | Kelly, Daniel | |
dc.date.accessioned | 2021-11-29T15:34:51Z | |
dc.date.available | 2021-11-29T15:34:51Z | |
dc.date.issued | 2021 | |
dc.date.submitted | 2021 | en |
dc.identifier.citation | Freeman F.E., Burdis R., Mahon O.R., Kelly D.J., Artzi N., A Spheroid Model of Early and Late-Stage Osteosarcoma Mimicking the Divergent Relationship between Tumor Elimination and Bone Regeneration, Advanced Healthcare Materials, 2021 | en |
dc.identifier.issn | 21922659 21922640 | |
dc.identifier.other | Y | |
dc.identifier.uri | http://hdl.handle.net/2262/97601 | |
dc.description | PUBLISHED | en |
dc.description.abstract | Osteosarcoma is the most diagnosed bone tumor in children. The use of tissue engineering strategies after malignant tumor resection remains a subject of scientific controversy. As a result, there is limited research that focuses on bone regeneration postresection, which is further compromised following chemotherapy. This study aims to develop the first co-culture spheroid model for osteosarcoma, to understand the divergent relationship between tumor elimination and bone regeneration. By manipulating the ratio of stromal to osteosarcoma cells the modelled cancer state (early/late) is modified, as is evident by the increased tumor growth rates and an upregulation of a panel of well-established osteosarcoma prognostic genes. Validation of the authors' model is conducted by analyzing its ability to mimic the cytotoxic effects of the FDA-approved chemotherapeutic Doxorubicin. Next, the model is used to investigate what effect osteogenic supplements have, if any, on tumor growth. When their model is treated with osteogenic supplements, there is a stimulatory effect on the surrounding stromal cells. However, when treated with chemotherapeutics this stimulatory effect is significantly diminished. Together, the results of this study present a novel multicellular model of osteosarcoma and provide a unique platform for screening potential therapeutic options for osteosarcoma before conducting in vivo experiments. | en |
dc.language.iso | en | en |
dc.relation.ispartofseries | Advanced Healthcare Materials; | |
dc.rights | Y | en |
dc.subject | Osteosarcoma | en |
dc.subject | Biological Models | en |
dc.subject | Cellular Spheroids | en |
dc.subject | Growth Factors | en |
dc.subject | Chemotherapies | en |
dc.subject | Bone Regeneration | en |
dc.title | A Spheroid Model of Early and Late-Stage Osteosarcoma Mimicking the Divergent Relationship between Tumor Elimination and Bone Regeneration | en |
dc.type | Journal Article | en |
dc.type.supercollection | scholarly_publications | en |
dc.type.supercollection | refereed_publications | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/freemanf | |
dc.identifier.peoplefinderurl | http://people.tcd.ie/kellyd9 | |
dc.identifier.rssinternalid | 235185 | |
dc.identifier.doi | http://dx.doi.org/10.1002/adhm.202101296 | |
dc.relation.ecprojectid | info:eu-repo/grantAgreement/EC/FP7/839150 | |
dc.rights.ecaccessrights | openAccess | |
dc.subject.TCDTheme | Cancer | en |
dc.subject.TCDTag | BONE REGENERATION | en |
dc.subject.TCDTag | OSTEOSARCOMA | en |
dc.contributor.sponsor | European Union (EU) | en |
dc.contributor.sponsorGrantNumber | 839150 | en |